RxDoctor Payments Data

Tara Bunch

Nurse Practitioner · Nacogdoches, TXNPI 1164987715

Payments from drug & device makers

$1,944in general payments, 2019–2025

Across 119 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$529
  • GSK$321
  • Boehringer Ingelheim$236
  • Actelion Pharmaceuticals US, Inc.$165
  • Regeneron Healthcare Solutions, Inc.$123
  • Sanofi$60
  • plus $509 from 16 others

What the payments were for

  • Food & beverage$1,944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,944 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$12,033
Medicare patients
86
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$17,428
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,584
XareltoRivaroxaban11$11,256
JardianceEmpagliflozin15$8,170
Gabapentin70$1,301
Atorvastatin Calcium72$854
Oxcarbazepine12$696
Quetiapine Fumarate15$682
Levothyroxine Sodium71$623
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$617
Rosuvastatin Calcium27$531
Potassium Chloride32$457
Lisinopril47$399
Escitalopram Oxalate33$364
Metoprolol Succinate35$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$17,42822 claims
AstraZenecaBreztri Aerosphere$529$13,58422 claims
Johnson & JohnsonXarelto$27$11,25611 claims
Boehringer IngelheimJardiance$236$8,17015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →